Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121834 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3050258 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT02121834 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 63 participants.
The verdict
NCT02121834, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
This is a multiple dose study of LY3050258 in healthy men and postmenopausal women. This study will evaluate the safety and how well the body tolerates LY3050258. It will last approximately 14 weeks with a 2 week follow-up appointment after the last treatment with study drug.
Interventions
- DRUG Placebo
- DRUG LY3050258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02121834
The ClinicalTrials.gov registry entry for NCT02121834 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02121834 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02121834 about?
NCT02121834 is a clinical study titled "A Study of LY3050258 in Healthy Participants". This is a multiple dose study of LY3050258 in healthy men and postmenopausal women. This study will evaluate the safety and how well the body tolerates LY3050258. It will last approximately 14 weeks with a 2 week follow-up appointment after the last treatment with study drug.
What is the current status of trial NCT02121834?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2014-06. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02121834?
The interventions under investigation include: Placebo (DRUG), LY3050258 (DRUG).
Who is sponsoring clinical trial NCT02121834?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.